# Insmed, Inc. (INSM) — Stock CV

Insmed, Inc. is a $21.9B healthcare company. It holds more cash than debt.

> Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare.

## Identity

- **Ticker**: INSM
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: BRIDGEWATER, NJ
- **Employees**: 1 664
- **Website**: https://www.insmed.com
- **Market cap**: $21.9B
- **Last price**: $100.50
- **Financial profile**: Strained

## Vitals (TTM)

- **Net income**: -$875M
- **Free cash flow**: -$808M
- **Net cash**: $889M

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 25 |
| Growth | 0 |
| Profitability | 0 |
| Health | 50 |
| Quality | 5 |
| Moat | 25 |

## Qualifications (beginner checklist) — 3 of 9 passed

- [x] Revenue growing — +35.2% YoY
- [ ] Profitable — -$875M TTM
- [ ] Profit growing — -39.7% YoY
- [ ] Generates cash — -$808M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $21.9B market cap
- [ ] Not printing shares — +77.5% shares over ~5y
- [ ] Proven track record — 0/10 profitable years
- [ ] Financially stable — health score 25/100

## Experience (career milestones)

- **FY2024** — Became debt-free: cash now exceeds total debt
- **1968** — He became a leading opponent of its practices

## Strengths

- High gross margin (83.5%)
- Net cash position after subtracting debt from cash

## Watch-outs

- Not profitable — 76.9% net margin
- Negative free cash flow (-$807.7M)
- Thin interest coverage (-54.0×)
- Loss-making in 10 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $188M | -$435M | -$371M |
| FY2022 | $245M | -$482M | -$410M |
| FY2023 | $305M | -$750M | -$550M |
| FY2024 | $364M | -$914M | -$706M |
| FY2025 | — | -$1.28B | -$968M |

---

Source: https://stockcv.com/INSM — derived from company filings; may be delayed or incomplete. Information, not investment advice.